Insta
Biggest Pharma Sector Deal Of 2020: AstraZeneca To Buy US-Based Biotech Major Alexion For $39 Billion
AstraZeneca
In a major deal, British pharmaceuticals behemoth AstraZeneca has announced that it is buying the United States (US) based biotechnology major Alexion at a price tag of $39 billion, reports Hindustan Times.
AstraZeneca, which has developed the Covishield vaccine in a partnership with the University of Oxford, has said that it is acquiring Alexion to boost its work on immunology.
As per AstraZeneca's chief executive Pascal Soroit, Alexion is an established leader in complement biology and has brought life-changing benefits to patients with rare diseases.
The $39 billion deal would mark the biggest such transaction in the pharma sector globally in the year 2020. It is expected to close in the third quarter of 2021, and Alexion shareholders will own 15 percent of the combined company. It will give AstraZeneca a significant presence in areas such as treating blood disorders.
It should be noted that since taking over as the chief executive of AstraZeneca in 2012, Soriot has pushed the pharma major into lucrative businesses like cancer therapies.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
